pharma
dog
News
when
Latest
Archive
by source
All Sources
Sources Page
Jobs
department
Clinical
Regulatory
Medical Affairs
Commercial
R&D / Discovery
Biostatistics / Data
Manufacturing / CMC
Market Access
therapeutic area
Oncology
Immunology
Neuroscience
Cardiovascular
Metabolic
Rare Disease
Infectious Disease
location & type
Remote Only
US Only
California
Massachusetts
Internships
Phase 3 Roles
All Jobs →
Drugs
by stage
Marketed
Phase 3
Phase 2
Phase 1
Preclinical
browse
Most catalysts
Recently active
All drugs →
Companies
Patent cliff
Calendar
what
Trial readouts
PDUFA dates
Approvals
Earnings
when
Upcoming
Month grid
Recently passed
◐
Sign In
Subscribe
home
jobs
news
search
ABBVIE · news · pharmadog
← back to ABBVIE
News mentioning ABBVIE
148
stories
7h
Genentech pens $1.27B deal to access Alector’s preclinical blood-brain barrier asset
biospace
18h
Genmab’s latest phase 2 data spur claim ADC is ‘clearly superior’ to AbbVie’s Elahere
fiercebiotech
3d
BMO most bullish on Merck's, bearish on BMS’ plans to contend with patent cliffs
biospace
3d
Foghorn cuts 40% of workforce
biospace
3d
Sarepta could be ‘potential turnaround story’ with catalysts lined up into 2027
biospace
4d
Chutes & Ladders—Bayer taps new chief medical officer; Cantor appointed PhRMA CEO
fiercebiotech
4d
3 takeaways from a European obesity scientific meeting
biopharma dive
4d
Merck’s antibody impresses with ‘highly competitive’ data in chronic skin disease
biospace
4d
Pfizer’s eczema drug clears skin in mid-stage trial
biopharma dive
4d
The top 12 companies hiring in biopharma now
biospace
5d
AbbVie's eczema drug shows benefit in Phase 2; BioMarin lays off 117
endpoints
5d
PhRMA names next CEO; Pierre Fabre takes third swing at Ebvallo approval
biopharma dive
5d
AstraZeneca buys into Summit, UniQure drops on 4-year data, FDA on a roll
biospace
5d
Opinion: America’s biotech race with China must be won at home
stat
6d
STAT+: Beam Therapeutics sues Chinese biotech, VC-backed startup, alleging theft of intellectual property
stat
6d
STAT+: Overton won’t get a vote before midterms
stat
6d
STAT+: AstraZeneca invests $2 billion in Summit Therapeutics
stat
6d
Enanta sheds staffers as key antiviral, immunology readouts loom
fiercebiotech
6d
AstraZeneca invests $2B in Summit, gaining ‘seat at the table’ for PD-1/VEGF drug push
biopharma dive
6d
STAT+: UniQure’s gene therapy continues to slow Huntington’s progression after four years
stat
6d
STAT+: Drug pricing, Medicaid, and research funding: The key policy issues at stake in the midterms
stat
7d
Risk from toxic metals can persist months after wildfires, Maui study finds
stat
7d
ai3Bio emerging from stealth to ‘take the gun out of the hands of the immune system’
fiercebiotech
7d
STAT+: It really is bleak out there, and list prices matter
stat
7d
STAT+: AbbVie wins FDA nod for Parkinson’s pill
stat
7d
AbbVie wins FDA approval for Parkinson’s drug from $8.7B Cerevel takeover
biospace
7d
6 immunology targets to sustain a mammoth I&I market
biospace
9d
AbbVie's next-gen dopamine therapy for Parkinson's gets FDA approval
endpoints
10d
ADARx raises $446M in biotech’s third largest IPO of 2026, City files to go public
biospace
10d
ADARx scores upsized $446M IPO, while fellow RNA biotech City maps out Nasdaq plans
fiercebiotech
← prev
page 1 of 5
next →
